Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Description

This randomized placebo-controlled double-blind phase II trial tests whether fecal microorganism (microbiota) transplantation prevents severe acute graft versus host disease in adults undergoing allogeneic hematopoietic cell transplantation (HCT). Fecal microbiota transplantation involves receiving processed fecal material orally after allogeneic HCT in order to establish a healthy gut microbiota. Gut microbiota undergoes major alterations during allogeneic HCT because of antibiotic exposures, nutritional changes, and chemotherapy administration. Establishing a healthy gut microbiota via fecal transplantation may help prevent acute graft versus host disease in patients undergoing allogeneic HCT.

Conditions

Acute Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm

Talk to us

Study Overview

On this page

Study Details

Study overview

This randomized placebo-controlled double-blind phase II trial tests whether fecal microorganism (microbiota) transplantation prevents severe acute graft versus host disease in adults undergoing allogeneic hematopoietic cell transplantation (HCT). Fecal microbiota transplantation involves receiving processed fecal material orally after allogeneic HCT in order to establish a healthy gut microbiota. Gut microbiota undergoes major alterations during allogeneic HCT because of antibiotic exposures, nutritional changes, and chemotherapy administration. Establishing a healthy gut microbiota via fecal transplantation may help prevent acute graft versus host disease in patients undergoing allogeneic HCT.

Fecal Microbiota Transplantation to Prevent Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Fecal Microbiota Transplantation for the Prevention of Acute Graft Versus Host Disease in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Condition
Acute Graft Versus Host Disease
Intervention / Treatment

-

Contacts and Locations

Seattle

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States, 98109

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age \>= 18
  • * Signed informed consent
  • * Able to take oral medications
  • * Planned T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed
  • * Planned GVHD prophylaxis using one of the following regimens:
  • * Calcineurin inhibitor (tacrolimus or cyclosporine) plus methotrexate
  • * Calcineurin inhibitor (tacrolimus or cyclosporine) plus mycophenolate mofetil (MMF)
  • * Sirolimus plus cyclosporine plus MMF
  • * Post-transplant cyclophosphamide plus calcineurin inhibitor (with or without MMF or sirolimus)
  • * One of the following HCT donor types:
  • * Human leukocyte antigen (HLA)-matched sibling donor
  • * 9/10 or 10/10 HLA-matched unrelated donor
  • * HLA- haploidentical donor
  • * Cord blood
  • * Willing to use at least 1 accepted method of contraception until day 180 after transplant and agree to not donate eggs/sperm for 180 days after
  • * Not pregnant or breast feeding
  • * ELIGIBILITY CRITERIA FOR RANDOMIZATION: Absolute neutrophil count (ANC) recovery to \> 0.5 x 10\^9/L from nadir, without ongoing growth factor support
  • * ELIGIBILITY CRITERIA FOR RANDOMIZATION: Discontinuation of all antibacterial antibiotics (except those used for Pneumocystis jiroveci prophylaxis) for 2 days
  • * ELIGIBILITY CRITERIA FOR RANDOMIZATION: Resolution of all acute toxicities (other than anemia and thrombocytopenia) to Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or lower
  • * ELIGIBILITY CRITERIA FOR RANDOMIZATION: Ability to swallow capsules
  • * ELIGIBILITY CRITERIA FOR RANDOMIZATION: No grade II-IV acute GVHD
  • * ELIGIBILITY CRITERIA FOR RANDOMIZATION: No moderate to severe chronic GVHD
  • * ELIGIBILITY CRITERIA FOR RANDOMIZATION: No concurrent antibiotics to treat infections. Prophylactic antiviral and antifungal antibiotics used to prevent infections are allowed
  • * Severe food allergy in the form of anaphylaxis or attributable symptoms requiring hospitalization
  • * History of chronic aspiration or conditions predisposing to aspiration (e.g. neuromuscular disorders)
  • * Receiving or planned to receive other experimental agents (including ex vivo T-cell depletion) to prevent GVHD. The use of other experimental agents is prohibited unless approved by the principal investigator (PI) of the other trial

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Fred Hutchinson Cancer Center,

Armin Rashidi, PRINCIPAL_INVESTIGATOR, Fred Hutch/University of Washington Cancer Consortium

Study Record Dates

2026-09-30